Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3461 - Influence of plasma T790M mutation on clinical decision after 1st generation EGFR-TKI resistance in a Real-world study


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Translational Research;  Non-Small Cell Lung Cancer


Shirong Zhang


Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380


S. Zhang1, L. Zhu2, B. Xia2, X. Chen3, S. Ma2

Author affiliations

  • 1 Hangzhou Translational Medicine Research Center, Hangzhou First People’s Hospital, Nanjing medical university, 310006 - Hangzhou/CN
  • 2 Radiation Oncology, Hangzhou First People’s Hospital, Nanjing medical university, Hangzhou/CN
  • 3 Medical Oncology, Hangzhou First People’s Hospital, Nanjing medical university, Hangzhou/CN


Abstract 3461


T790M mutation detection in circulating tumor DNA (ctDNA) has shown great potential in clinical application. However, few studies reported the influence of plasma T790M mutation on selection of clinical treatment and survival time after first generation TKI resistance.


307 patients with advanced or recurrent NSCLC who had progressed during EGFR-TKIs treatment were enrolled prospectively (NCT02418234) from March 2015 to March 2016. Blood samples were drawn within two weeks from PD occurred. T790M mutations were evaluated by droplet digital PCR. We undertook follow-up every 3 months by phone till April 2017. The median follow-up time was 11 months (range, 2 to 22 months).


Our results showed that the median survival time after TKI progression was 17.5 months (95%CI, 15-20 months) and six kinds of treatments were used in these patients, including continuation of TKI (27.0%), AZD9291 (27.7%), chemotherapy with or without radiotherapy (15.3%), TKI combined with chemo/RT (6.5%), switch to another TKI (2.6%) and best supportive care (11.4%). 88.6% of patients received subsequent treatment. T790M- patients were likely to receive continuation of original TKIs, which accords for 29.5% (52/176), the percentage of switch to another TKI is the lowest (2.8%, 5/176). In T790M+ patients, AZD9291 is the first choice as the subsequent treatment, which accords for 38.9% (51/131). Switch to another TKI (2.2%, 3/131) and TKI combined with chemo/RT (6.1%, 8/131) is the least selection. Although most T790M- patients received continuation of original TKIs, combination of TKI and chemotherapy/radiotherapy seems to be a better choice, which got the longest survival than other treatment. For T790M+ patients, patients who choose AZD9291 had the longest survival.


T790M status in ctDNA have the great influence on clinical decision of the subsequent treatment, AZD9291 is the most frequent choice for the plasma T790M+ patients, which contributed the longest survival after 1st generation EGFR-TKI resistance.

Clinical trial identification


Legal entity responsible for the study

Shenglin Ma


Projects of Medical and Health Technology in Zhejiang Province (WKJ-2J-1532)


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.